MEXICOR EFFECTIVENESS IN PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME

Abstract

In total, the study included 60 45-64-year-old patients in early post-infarction phase, with chronic heart failure (CHF), Functional Class II-III, and metabolic syndrome (MS). The patients were randomised into two groups (n=30 in each group). In the main group, standard CHF therapy was extended by adding mexicor (0,4 g/d). The study lasted for 12 weeks. Cytoprotector mexicor, as a part of complex CHF therapy, reduced HF severity, improved quality of life, and demonstrated anti-anginal effects. In MS patients, mexicor improved myocardial contractibility, diastolic function, autonomous control of heart function, glomerular filtration rate, lipid and carbohydrate metabolism, and insulin sensitivity.

Keywords

• metabolic syndrome
• chronic heart failure
• mexicor
• insulin resistance
• carbohydrate and lipid metabolism